Navigation Links
Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries
Date:9/26/2007

Encased self-locking sliding knot enables surgeons to control tension,

avoid tissue damage

ANDOVER, Mass., Sept. 26 /PRNewswire-FirstCall/ -- Smith & Nephew's (NYSE: SNN; LSE: SN) Endoscopy Division today announced the launch of the KINSA RC 5.5 Suture Anchor, designed to provide secure repair of shoulder injuries stemming from tears to the rotator cuff -- the group of muscles and tendons that control shoulder motion.

Surgeons can repair these injuries using arthroscopic -- or minimally invasive -- techniques with specialized instruments and devices such as the KINSA RC Suture Anchor, which re-attaches the torn tissue to restore mobility.

The KINSA RC Suture Anchor is the second in Smith & Nephew Endoscopy's line of KINSA suture anchors. The original KINSA anchor, for treatment of shoulder instability, was released in 2006. Both KINSA anchors encase a sliding, self-locking knot that permits the surgeon to secure the repair without tying knots on top of the tissue. Surgical knots in arthroscopic repairs can sometimes loosen or cause irritation of surrounding tissue. The KINSA RC anchor instead delivers "low profile" repair, without knots or protrusions to interfere with the joint motion.

Successful rotator cuff repair requires that a suture anchor sit securely in the cortical, or dense outer layer of bone, and that the surgeon controls the tension of the sutures that hold repaired tissue in place.

The anchor is well suited for "double-row" fixation, a procedure that clinical studies have shown delivers the superior rotator cuff repair and shoulder mobility. This technique calls for the surgeon to anchor the rotator cuff tissue at several points, distributing the strength of fixation across the shoulder.

A surgeon taps the anchor into the bone surface, and then seats it with a final twist. The surgeon controls the amount of tension applied to the repair by manually tightening the KINSA suture. Surgeons who use competing anchors don't have total control over the tension.

"Its design allows me to properly sink the anchor first, and then apply the amount of tension for optimal tissue-to-bone contact to promote healing," said Dr. Michael Terry, orthopedic surgeon based at the University of Chicago. "This is important because too much tension can interfere with blood flow in the tissue and compromise healing.

"Another benefit of this system is that it is so easy to use," Dr. Terry said. "There are no knots to tie and the instrumentation is simple and familiar."

The KINSA RC anchor is small -- about 1/2-inch in length -- and made from a unique, implantable PEEK-OPTIMA(R) polymer from Invibio(R), which closely matches the density of cortical bone. The implants deliver strong repair but do not show up on X-rays or distort MRIs, as metal anchors would.

"The KINSA RC Suture Anchor enhances our innovative line of shoulder fixation devices, which have been designed to provide the best possible repair for patients, and the most efficient delivery for busy shoulder surgeons," said Joe Darling, senior vice president and general manager of Smith & Nephew Endoscopy's Arthroscopic Repair strategic business unit.

About Smith & Nephew

Smith & Nephew is a global medical technology business, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company has 9,600 employees and operates in 31 countries around the world. Annual sales in 2006 were nearly $2.8 billion.

This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based

Contact: Joe Metzger

Smith & Nephew Endoscopy

(978) 749-1330


'/>"/>
SOURCE Smith & Nephew
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. Iodex goes to SmithKline Beecham consumer Healthcare
3. GlaxoSmithKline To Cultivate Non-Smoking Environment
4. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
5. FDA Mislead On Asthma Drug By GlaxoSmithKline
6. GlaxoSmithKline Defends Its Products
7. GlaxoSmithKline launches diabetes and cancer drugs
8. Generic Products Compete With GlaxoSmithKline
9. New Cervical Cancer Vaccine to Be Launched By Glaxo Smithkline
10. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
11. GlaxoSmithKlines Zofran Helps In Treatment Of Dehydration In Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... The Dan Carlisle Agency, an Alabama-owned firm ... announcing the launch of a charity drive to raise support and awareness for ... children in Birmingham has grown steadily since the 1980’s, and the Pathways organization ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a family owned ... and around the Hancock County area, is announcing the launch of a charity effort ... The Hancock County Food Pantry has worked for more than 30 years to meet ...
(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry ... Control through a new partnership with Splashtop Inc. This remote control for Android ... to help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... ANGELES , Dec. 8, 2016  Hanson ... manufacturing of dissolution testing and diffusion testing instruments ... been acquired by Teledyne Instruments, Inc. ("Teledyne"). The ... long-proven line of precision testing instruments, as well ... accelerating development of new products and services. ...
(Date:12/8/2016)... CANTEL MEDICAL CORP. (NYSE: CMD ) ... per diluted share, on a 22.1% increase in sales to ... 2016. This compares with net income of $14,254,000, or $0.34 ... quarter ended October 31, 2015. Non-GAAP net ... 2016 to $21,323,000, or $0.51 per diluted share, compared with ...
(Date:12/8/2016)... and SAN DIEGO , Dec. 8, 2016 ... solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech ... and the Genome Institute of Singapore ... new joint venture between Novogene and AITbiotech – will establish ... Singapore .   The new centre ...
Breaking Medicine Technology: